Table 6 Predictive analysis of GR methylation groups
GR methylation group | Treatment | # of patients | OS | DFS | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
5-year OS | Hazard ratio [95% CI] | P | P value for interaction | 5-year DFS | Hazard ratio [95% CI] | P | P value for interaction | |||
C methylated | Placebo | 27 | 92.6% | 1 | 0.82 | 0.427 | 81.5% | 1 | 0.789 | 0.723 |
Tamoxifen | 15 | 93.3% | 0.744 [0.058–9.598] |  | 86.7% | 1.221 [0.266–5.597] |  | |||
Both C and U unmethylated | Placebo | 62 | 90.3% | 1 | 0.596 | 72.6% | 1 | 0.328 | ||
Tamoxifen | 57 | 87.5% | 1.258 [0.563–2.493] |  | 73.2% | 0.755 [0.418–1.361] |  | |||
U methylated, no C methylation | Placebo | 23 | 65.2% | 1 | 0.105 | 47.8% | 1 | 0.081 | ||
Tamoxifen | 22 | 86.4% | 0.414 [0.142–1.203] |  | 68.2% | 0.430 [0.166–1.110] |  | |||